-
Gates Ventures and the Alzheimer’s Disease Data Initiative (ADDI) to Partner with the Global Alzheimer’s Platform Foundation® (GAP) and Other Industry Leaders on Breakthrough Alzheimer’s Study Posted on by Taylor Disselhorst in Press Releases
-
Wash U Neurologist Explains Controversy Behind New Alzheimer’s Drug: Aduhelm Posted on by Taylor Disselhorst in In the News
-
GAP’s Dr. Tamiko MaGee-Rodgers Speaks About Minority Involvement in Clinical Trials Posted on by Taylor Disselhorst in In the News
-
Local Researchers Help Black & Brown Communities Detect Factors for Alzheimer’s Posted on by Taylor Disselhorst in In the News
-
Reversing the Trend: Making Clinical Trials More Diverse Posted on by Taylor Disselhorst in In the News
-
First Patient Receives Controversial Biogen Alzheimer’s Drug Posted on by Taylor Disselhorst in In the News
-
Blacks Continue To Have Twice The Incidence Rates For Alzheimer’s As Whites Posted on by Taylor Disselhorst in In the News
-
Doctors Fear a Controversial New Alzheimer’s Drug Will Get in the Way of Better Treatments Posted on by Taylor Disselhorst in In the News
-
Free Access To High-Cost Aducanumab May Incentivize Phase IV Trial Participants Posted on by Taylor Disselhorst in In the News
-
FDA Approves New Drug to Treat Alzheimer’s Disease Posted on by Taylor Disselhorst in In the News
